Tejapatra: Traditional Uses, Evidence & Safety

TL;DR

Tejapatra is the dried mature leaf of Cinnamomum tamala, an evergreen Himalayan tree in the laurel family, used as spice and Ayurvedic medicine. The pharmacopoeia classifies it heating, sharp, and appetite-kindling. Laboratory and animal studies show real pharmacological activity, especially around blood sugar. No human trial exists, and market leaves are routinely substituted with other Cinnamomum species.

What it is

The Ayurvedic Pharmacopoeia of India defines the drug Tvakpatra as the dried mature leaves of Cinnamomum tamala (Buch.-Ham.) Nees & Eberm., family Lauraceae: a small evergreen tree up to 7.5 m tall, growing in the tropical and sub-tropical Himalayas between 900 and 2300 m, with leaves collected in dry weather around October to March from roughly ten-year-old plants (API Part I, monograph 72). Hindi calls it tejpatta; Sanskrit, tamalapatra; English trade names include Indian bay leaf and Indian cassia.

The pharmacopoeial taste-and-action profile runs like this. Rasa: katu, tikta, madhura (pungent, bitter, sweet). Guna: ruksha, laghu, tikshna (dry, light, sharp). Virya: ushna (heating). Vipaka: katu. Karma: kaphavatahara, vishaghna, kanthashuddhikara, rucya, meaning it pacifies kapha and vata, counteracts toxicity, clears the throat, and kindles appetite (same monograph). The official constituents list is short: essential oil, tannin, and mucilage. A GC-MS analysis of the leaf oil found 31 constituents, with cinnamaldehyde the dominant one at 44.898% (Kumar, Vasudeva & Sharma).

Now the identity problem, because it matters before anything else. Tejapatra is the leaf. Cinnamon is the bark. Mediterranean bay leaf (Laurus nobilis) is a different plant in a different genus. And a peer-reviewed market survey in AYU found that South Indian crude-drug markets routinely sell other Cinnamomum species as tamalapatra, including C. malabatrum, with microscopy needed to tell the powdered drug apart (PubMed 24250130). An Ayurvedic college teaching document puts it bluntly: north and south India use different plants as tamalapatra (SSM Ayurvedic College monograph). When the label says tejapatra, the leaf inside is not always C. tamala. I wish the trade were cleaner than that. It is not.

Traditional use

The pharmacopoeia records these therapeutic uses: mukhashosha (dryness of mouth), trishna (thirst), kanthamukharoga (throat and mouth disorders), pinasa (chronic nasal catarrh), krimiroga (worm infestation), vastiroga (urinary bladder disorders), arsha (haemorrhoids), and hridroga (heart disorders) (API Part I, monograph 72). The two flagship formulations named are Sitopaladi Churna, the classic cough preparation, and Caturjata Churna.

The leaf's textual home is the nighantus, the materia-medica compendia, rather than the three great treatises. Bhavaprakasha Nighantu places it in the karpuradi varga, Dhanvantari Nighantu in the shatpushpadi varga, Raja Nighantu in the pippalyadi varga (LiveAyurved medicinal-plant reference). I could not verify a quotable line from Charaka, Sushruta, or Vagbhata in the sources available to me, so I will not pretend one exists for this article.

I say what I say on every page here: these are traditional claims, not clinical proof. The laboratory record is below, and the two are not the same thing.

What modern research says

Blood sugar, lipids, and antioxidants (animal study plus in-vitro chemistry)

The strongest single preclinical paper is from Kumar, Vasudeva, and Sharma, published in Cardiovascular Diabetology in 2012. They gave streptozotocin-induced diabetic rats the leaf essential oil at 100 and 200 mg/kg and cinnamaldehyde at 20 mg/kg for 28 days. Blood glucose fell. Glycosylated haemoglobin and total plasma cholesterol fell. Plasma insulin, liver glycogen, and body weight rose. The effects were comparable to glibenclamide at 0.6 mg/kg, the standard-drug control. In test-tube models the oil showed significant free-radical scavenging, and in the rats it lowered malondialdehyde and raised reduced glutathione (full text).

Read that paragraph again and notice what it does not say. Rats. Diabetic rats, specifically. A separate animal study found the ethanolic leaf extract lowered blood glucose in both normal and streptozotocin-diabetic rats (review, ref 27). The 2020 Pharmacognosy Journal review by Tiwari and Talreja compiles this whole preclinical pattern, antioxidant through hypolipidaemic, in one place (Tiwari & Talreja, 2020). None of it has been tested in people.

Kidney protection against a toxin (animal study)

In rabbits given the kidney-damaging drug gentamicin, daily leaf extract at 200 mg/kg protected renal function: blood urea nitrogen, serum creatinine, creatinine clearance, uric acid, and urinary protein all moved in the right direction, with histopathology to back it up. That is Ullah et al., Tropical Journal of Pharmaceutical Research, 2013 (via review). Rabbits, not patients.

Inflammation and ulcer (animal and in-vitro studies)

An aqueous leaf extract at 100, 200, and 400 mg/kg reduced carrageenan-induced paw swelling in rats and reduced acetic-acid-induced vascular permeability; in vitro it stabilized membranes in a dose-dependent manner (Gambhire et al., 2009, via review). A hydro-alcoholic extract protected rat stomach lining against three different ulcer triggers: cold-restraint stress, ethanol, and pylorus ligation (via review). Consistent with the throat-and-mouth uses above, suggestive of nothing proven.

Antimicrobial activity (in-vitro studies)

Leaf oil and extracts inhibited bacteria and fungi in agar-diffusion assays, including E. coli, Bacillus subtilis, Aspergillus niger, and Candida albicans (via review). Test-tube inhibition. Useful for food preservation; not a medicine yet.

Dosage

The Ayurvedic Pharmacopoeia of India gives a dose: 1 to 3 g of the drug in powder form (monograph 72). That is a pharmacopoeial posology, not a figure from a human safety trial, and it should not be read as one.

What the evidence does not support (yet)

No human clinical trial of tejapatra, for blood sugar or any other indication, was identified in the searches conducted for this article. The 2020 review also compiles claims about anticancer, antianxiety, antimalarial, and skin-whitening activity that rest on in-vitro or isolated animal work, and it treats all of them as established. I do not. The antidiabetic signal in rats is the most replicated finding in the literature, and even it has never crossed into a human study. The substitution problem above means some published work may not have used C. tamala material at all.

Safety & contraindications

Tejapatra is a daily cooking spice across South Asia, and that culinary history is reassuring in food amounts. It is not safety evidence for medicinal doses, and the two should not be confused.

No human safety data for tejapatra were identified. No data exist on pregnancy, breastfeeding, or drug interactions. The one toxicity figure available is animal: in the rat study above, the leaf oil was non-lethal up to 1000 mg/kg, while 2000 mg/kg killed half the animals (Kumar et al., 2012). An animal finding, not human safety evidence.

Two cautions follow from the traditional side. The drug is ushna, heating, so classical reasoning advises care in pitta-aggravated conditions. And given the documented adulteration, a packet of tejapatra may contain a different Cinnamomum species with a different chemistry, so composition is uncertain without verification. I do not soften any of that.

FAQs

What plant is tejapatra?

The dried mature leaves of Cinnamomum tamala, the Indian bay leaf, a Lauraceae tree of the Himalayas. It is the leaf, not the bark, and it is not Mediterranean bay leaf (Laurus nobilis) (API Part I, monograph 72).

What is tejapatra used for in Ayurveda?

Traditionally for appetite loss, throat and mouth disorders, chronic nasal catarrh, worms, bladder disorders, haemorrhoids, and heart complaints, and as an ingredient in Sitopaladi Churna and Caturjata Churna. These are traditional uses, not clinically proven effects. I keep that distinction on every page.

Does research support tejapatra for blood sugar?

Only in animals. Leaf oil and extracts lowered blood glucose and improved lipid and antioxidant markers in diabetic rats (Kumar et al., 2012). No human trial has tested it. That is the entire honest answer.

Is tejapatra the same as cinnamon?

No. Cinnamon is the bark of Cinnamomum species (tvak in Ayurveda); tejapatra is the leaf of Cinnamomum tamala. They share aromatic chemistry, including cinnamaldehyde, but they are different drugs with different pharmacopoeial monographs.

Why might the tejapatra I buy not be tejapatra?

Because substitution is documented. A 2013 AYU market survey found other Cinnamomum species, including C. malabatrum, sold as tamalapatra in South Indian markets, distinguishable only by microscopy once powdered (PubMed 24250130).

The Ayurvedic Pharmacopoeia of India lists 1 to 3 g of the leaf powder. That is a pharmacopoeial figure, not a dose proven safe in a human trial. Anyone who gives you a therapeutic dose with confidence is improvising.

Is tejapatra safe in pregnancy?

There are no data. The heating classification and the complete absence of pregnancy studies mean medicinal doses should not be assumed safe in pregnancy or breastfeeding. Talk to a qualified practitioner.

Voices

The classical shelf

Tejapatra's classical presence is in the nighantus, the Ayurvedic materia-medica compendia: Bhavaprakasha files it in the karpuradi varga, Dhanvantari in the shatpushpadi varga, Raja in the pippalyadi varga (LiveAyurved medicinal-plant reference). The modern codification of that tradition is the pharmacopoeial monograph itself, which records the drug as kaphavatahara, vishaghna, kanthashuddhikara, and rucya, and names Sitopaladi Churna and Caturjata Churna among its formulations (API Part I, monograph 72).

The leaf also traveled further than most Ayurvedic drugs. A historical materia-medica compendium lists it under the names Folium Indicum and Malabathrum, citing Dioscorides' De Materia Medica (Ruellio edition, 1549) and Parkinson's Theatrum Botanicum (1640) (Medicine Traditions). The same page lists C. zeylanica and C. malabathrum as alternate sources, which shows the identity confusion is centuries old, not a modern market invention.

The modern laboratory

The most detailed modern voice is the Kumar, Vasudeva, and Sharma rat study: 31 oil constituents mapped by GC-MS, cinnamaldehyde dominant, and 28 days of dosing moving glucose, insulin, HbA1c, and cholesterol in diabetic rats comparably to glibenclamide (Cardiovascular Diabetology, 2012;11:95). The second is Ullah's rabbit study: leaf extract at 200 mg/kg per day shielding kidneys from gentamicin damage across every measured marker (Tropical Journal of Pharmaceutical Research, 2013;12(2):215-219). Both are preclinical. There is no clinical voice to quote because the clinical work has not been done.

Sources

The botanical definition, taste-and-action profile (rasa katu-tikta-madhura; guna ruksha-laghu-tikshna; virya ushna; vipaka katu; karma kaphavatahara, vishaghna, kanthashuddhikara, rucya), constituents, therapeutic uses, formulations, and the 1-3 g dose all come from the Ayurvedic Pharmacopoeia of India, Part I, monograph 72, Tvakpatra (mirror of the official text). The nighantu varga placements come from a medicinal-plant reference (LiveAyurved); the north-south regional identity note comes from an Ayurvedic college teaching monograph (SSM Ayurvedic College). The market-substitution finding is Sunil Kumar, AYU 2013;34(2):193-199 (PubMed 24250130). The animal evidence rests on Kumar, Vasudeva & Sharma, Cardiovascular Diabetology 2012;11:95 (DOI 10.1186/1475-2840-11-95), the 2020 Pharmacognosy Journal review by Tiwari & Talreja, 12(6)Suppl:1792-1796 (DOI 10.5530/pj.2020.12.241), which also catalogues the Ullah et al. 2013 rabbit nephroprotection study, the Gambhire et al. 2009 rat anti-inflammatory work, and the in-vitro antimicrobial findings, and a historical materia-medica compendium for the Folium Indicum/Malabathrum listing (Medicine Traditions).

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.